COMMUNIQUÉS West-GlobeNewswire

Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
08/03/2024
FARMINGTON HILLS, Mich., March 08, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule therapies for the [...]
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
08/03/2024
Two pivotal Phase 3 clinical trials studying soticlestat as a treatment for Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) completed enrollment; Takeda anticipates topline data readout by or before September [...]
FDA Delays Approval of Donanemab for the Treatment of Early-Stage Alzheimer’s
08/03/2024
Agency to convene an advisory committee to consider the drug WASHINGTON, March 08, 2024 (GLOBE NEWSWIRE) -- The maker of donanemab, Eli Lilly , announced today that the Food and Drug Administration (FDA) will convene an [...]
Arbutus to Participate in Two Upcoming Investor Conferences
08/03/2024
WARMINSTER, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for [...]
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
08/03/2024
NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI ® ( [...]
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
08/03/2024
Raised up to $140 million of non-dilutive non-recourse capital through a royalty-backed loan related to VABYSMO® from funds managed by Blue Owl Capital Received $15.5 million in cash payments related to our growing [...]
Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update
08/03/2024
Leadership Changes Led by Appointment of Co-Founder Thomas Jensen as Interim CEO and Jeremy Graff, Ph.D., former Eli Lilly Executive, as Executive Advisor Reduced Net Loss from Operations by 50% and Reduced Net Loss by [...]
SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder
08/03/2024
TEL AVIV, Israel, March 08, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders [...]
EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet
08/03/2024
Published results show EYLEA HD with extended 12- or 16-week dosing regimens demonstrated non-inferior vision gains to standard of care EYLEA ® (aflibercept) Injection 2 mg with fixed 8-week dosing in patients with wAMD [...]
Bio-Path Holdings Reports Full Year 2023 Financial Results
08/03/2024
Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, March 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® liposomal delivery and [...]
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
08/03/2024
HAMPTON, N.J., March 08, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on [...]
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
08/03/2024
Data adds to increasing body of evidence supporting positive modulation of the neurotrophic HGF system as a potential therapeutic approach for neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease [...]
As part of International Women’s Day 2024, Women’s Health Advocate calls on expeditious passage of C-64: An Act Respecting Pharmacare
08/03/2024
OTTAWA, March 08, 2024 (GLOBE NEWSWIRE) -- The Society of Obstetricians and Gynaecologist of Canada (SOGC) recognizes and celebrates the incredible contributions of women in Canadian society part International Women’s [...]
Dans le cadre de la Journée internationale des femmes de 2024, les professionnels de la santé des femmes demandent à ce que le projet de loi C-64, Loi concernant l’assurance médicaments, soit adopté rapidement
08/03/2024
OTTAWA, 08 mars 2024 (GLOBE NEWSWIRE) -- En cette Journée internationale des femmes, la Société des obstétriciens et gynécologues du Canada (SOGC) reconnaît et célèbre la contribution incroyable des femmes pour la [...]
Augmedix to Announce Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024
08/03/2024
SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading, ambient medical documentation and data solutions, announced today it will [...]
Galimedix Therapeutics presents new scientific data showing promising neuroprotective effects of GAL-201 for the treatment of Alzheimer’s disease at AD/PD™ 2024
08/03/2024
GAL-201 specifically targets and binds to misfolded Aβ monomers, preventing their aggregation to toxic Aβ oligomers and protofibrils As a consequence, consistent beneficial effects have been demonstrated on synaptic [...]
Crossject gender equality score reaches 96/100 in 2024
08/03/2024
Dijon, France, March 8, 2024 – 7:30 pm CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations, today announces its EU Gender [...]
Le Score de l’index Egalité femmes-hommes chez Crossject atteint 96/100 en 2024
08/03/2024
Dijon, France, 08 mars 2024 – 07:30 CET - Crossject (ISIN : FR0011716265 ; Euronext : ALCJ), une société pharmaceutique spécialisée qui développe des auto-injecteurs sans aiguille dédiés aux situations d’urgence, [...]
Hyloris to Report 2023 Full-Year Results on 14 March 2024
08/03/2024
Liège, Belgium – 08 February 2024, 07:00 AM CET – Non-regulated information – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL) , a specialty biopharma company committed to addressing unmet medical needs through [...]

Pages